Clinical Trial

"Evolution of Sexual Symptoms in Paraphilic Sexual Offenders With/Without Antiandrogen or SSRI Treatment"

Study acronym: ESPARA
Not Yet Recruiting
View on ClinicalTrials.gov →
Summary
The ESPARA study is a multicenter observational research project aiming to monitor, over a three-year period, the evolution of sexual symptoms in male sexual offenders with paraphilia, divided into three groups: receiving antiandrogen treatment, receiving selective serotonin reuptake inhibitors (SSRIs), or no pharmacological treatment. The primary objective is to assess changes in sexual desire intensity and deviant sexual behaviors, while secondary objectives include relapse rates, the role of psychiatric comorbidities, treatment tolerability, and various clinical, cognitive, and life-history factors.
Trial Details
NCT Number NCT07144943
Lead Sponsor Centre Hospitalier St Anne
Conditions Sexual Disorder, Physiological
Enrollment 200 participants
Start Date 2025-09-15
Primary Completion 2030-09 (estimated)
Study Completion 2030-09 (estimated)
Updated on ClinicalTrials.gov 2025-08-28